Initial treatment of cryptococcal meningitis in AIDS

Area of Science:

• Infectious Diseases
• Neuroscience
• Immunology

Background:

• Cryptococcal meningitis is a life-threatening opportunistic infection in individuals with advanced HIV/AIDS.
• Standard treatment involves amphotericin B followed by fluconazole, but treatment failures and toxicities remain concerns.

Purpose of the Study:

• To compare the efficacy of initial treatment with amphotericin B plus rifampin versus amphotericin B alone in patients with cryptococcal meningitis and AIDS.
• To evaluate the impact of adding rifampin on key clinical outcomes, including fungal clearance, fever resolution, mortality, and intracranial pressure.

Main Methods:

• An open-label, randomized, controlled, prospective clinical trial was conducted.
• Twenty patients were assigned to receive either amphotericin B plus rifampin or amphotericin B alone for two weeks, followed by fluconazole for eight weeks.
• Outcomes assessed included negative cerebrospinal fluid (CSF) cultures, time to normal body temperature, mortality, and CSF pressure.

Main Results:

• No significant differences were observed between the two groups regarding negative CSF cultures at weeks 2 and 10.
• Time to normal body temperature, patient mortality, and persistence of high CSF pressure did not differ significantly between the treatment arms.
• Elevated intracranial pressure was identified as a significant factor associated with mortality.

Conclusions:

• The addition of rifampin to amphotericin B does not offer a significant therapeutic advantage over amphotericin B monotherapy for acute cryptococcal meningitis in AIDS patients.
• Current treatment strategies remain critical, with a focus on managing elevated intracranial pressure to improve survival rates.